BioTelemetry Inc. (NASDAQ:BEAT) reached a new 52-week high during trading on Wednesday . The stock traded as high as $18.70 and last traded at $18.50, with a volume of 398,205 shares. The stock had previously closed at $17.67.

Separately, Zacks Investment Research lowered BioTelemetry from a “hold” rating to a “sell” rating in a research note on Tuesday, April 19th.

The stock has a market capitalization of $511.58 million and a P/E ratio of 46.43. The company has a 50 day moving average of $16.53 and a 200-day moving average of $13.34.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Tuesday, April 26th. The company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.10. The company earned $48.60 million during the quarter, compared to analyst estimates of $46.54 million. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.06 EPS. Equities research analysts anticipate that BioTelemetry Inc. will post $0.71 earnings per share for the current year.

Other institutional investors recently made changes to their positions in the company. Gabelli Funds LLC bought a new position in shares of BioTelemetry during the fourth quarter worth $1,190,000. Russell Frank Co raised its position in shares of BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock worth $2,933,000 after buying an additional 92,455 shares during the period. 1492 Capital Management LLC raised its position in shares of BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock worth $3,758,000 after buying an additional 32,932 shares during the period. Royce & Associates LLC raised its position in shares of BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock worth $7,086,000 after buying an additional 306,700 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock worth $11,612,000 after buying an additional 119,328 shares during the period.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.